← Back to all trials
Completed
NCT06854952
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
Conditions: Overweight or Obesity
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 167
Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Location: FALCON Research Site Birmingham Alabama
Summary
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Eligibility Criteria
Key Inclusion Criteria:
1. Female or male aged 18 to 75 years
2. Body mass index (BMI) of:
1. ≥ 30 kg/m\^2 to \< 50 kg/m\^2
OR
2. ≥ 27 kg/m\^2 to \< 30 kg/m\^2 with at least 1 weight-related comorbidity
3. HbA1c \< 6.5%
4. Stable self-reported body weight for at least 3 months prior to study (\< 5% body weight gain or loss)
Key Exclusion Criteria:
1. Have diabetes mellitus
2. Have obesity induced by medication or other diagnosed endocrinologic disorders
3. Have had or are planning surgical treatment or device-based therapy for obesity
4. Lifetime history of suicide attempt
Source: ClinicalTrials.gov (NCT06854952). StuddyBuddy aggregates publicly available trial information.
